Acting on its authorization to acquire up to 10% of its shares the H. Lundbeck Supervisory Board has resolved to initiate a share buyback program. Under the program H. Lundbeck will buy own shares for an amount of up to DKK 6 billion, cf. stock exchange announcement number 166 on 17th August 2005. During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on the Copenhagen Stock Exchange, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003. At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program. The following transactions have been made under the program: No. of shares Average Transaction value purchase price (DKK) (DKK) Accumulated, last 22,302,233 134.8888 3,008,321,140 announcement 23 August 2007 143,286 128.1109 18,356,493 24 August 2007 41,821 126.6620 5,297,130 27 August 2007 5,721 129.1111 738,644 28 August 2007 136,793 128.7835 17,616,680 29 August 2007 17,583 126.9831 2,232,744 30 August 2007 131,200 128.0216 16,796,436 31 August 2007 111,810 127.9499 14,306,081 Accumulated under the 22,890,447 134.7238 3,083,888,086 program Following the above buyback it is hereby announced that Lundbeck owns a total of 3,733,660 own shares at a nominal value of DKK 5, equal to 1.80% of the total number of 207,279,631 shares. The content of this release will have no influence on the Lundbeck Group's financial result for 2007. Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Director, Investor Relations Media Relations Manager +45 36 43 30 79 +45 36 43 26 38 +1 201 350 0187 ________________________ Stock Exchange Release No 291 - 31 August 2007 About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com